Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 20/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19409508 | 1.00 | MGLL (0.54) | MGLL | |
| SCHEMBL19421096 | 1.00 | MGLL (0.54) | MGLL | |
| SCHEMBL19421091 | 0.93 | MGLL (0.54) | MGLL | |
| SCHEMBL19409526 | 0.93 | MGLL (0.54) | MGLL | |
| SCHEMBL19409527 | 0.93 | MGLL (0.54) | MGLL | |
| SCHEMBL19421061 | 0.84 | MGLL (0.55) | MGLL | |
| SCHEMBL19409708 | 0.84 | MGLL (0.55) | MGLL | |
| SCHEMBL19409707 | 0.84 | MGLL (0.55) | MGLL | |
| SCHEMBL19421071 | 0.79 | MGLL (0.51) | MGLL | |
| SCHEMBL19409629 | 0.79 | MGLL (0.51) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436444-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10323026-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283406-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | MGLL 138/4885 |
| US-10323026-B2 | Heterocyclic compound | MAG, HTT, ACHE | MGLL 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.